Anti-PSMA Purified FOLH1 Monoclonal Antibody

Product Name

Anti-PSMA Purified FOLH1 Monoclonal Antibody

View all FOLH1 Antibodies

SKU/Catalog Number

M02846-2

Size

0.1 mg

Form

Liquid

Description

Boster Bio Anti-PSMA Purified FOLH1 Monoclonal Antibody (Catalog# M02846-2). Tested in WB, IHC-P, ICC application(s). This antibody reacts with Pig, Mouse, Rat, Human.

Storage & Handling

Store at 2-8°C. Do not freeze.

Cite This Product

Anti-PSMA Purified FOLH1 Monoclonal Antibody (Boster Biological Technology, Pleasanton CA, USA, Catalog # M02846-2)

Host

Mouse

Contents

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Clonality

Monoclonal

Clone Number

GCP-04

Isotype

Mouse IgG1

Immunogen

Recombinant fragment of human GCPII (amino acids 44-750) produced in S2 cells. The mouse monoclonal antibody GCP-04 recognizes amino acids 100-104 of extracellular domain of denaturated glutamate carboxypeptidase II (PSMA, NAALADase, FOLH1), an approximately 95-110 kDa transmembrane glycoprotein.

Cross-reactivity

This antibody does not cross-react with Thy-1.1 alloantigen.

Reactive Species

M02846-2 is reactive to FOLH1 in Human, Mouse, Pig, Rat

Observed Molecular Weight

42 kDa

Calculated molecular weight

84.3 kDa

Background of FOLH1

Glutamate carboxypeptidase II (GCPII), also known as N-acetyl-alpha-linked acidic dipeptidase I (NAALADase I), folate hydrolase (FOLH1), and prostate-specific membrane antigen (PSMA), is an approximately 95-110 kDa type II transmembrane glycoprotein expressed in various tissues. In nervous system GCPII cleaves abundant N-acetylaspartylglutamate, which is released from neurons in a calcium-dependent manner, to N-acetylaspartate and glutamate. As immoderate glutamate concentration is neurotoxic, GCPII contributes to pathological conditions regarding e.g. Alzheimer´s disease, Huntington´s disease, epilepsy, schizophrenia, stroke or neuropathic pain and appears to be an interesting therapeutic target. In jejunum GCPII hydrolyzes pteroylpoly-gamma-glutamate to folate and glutamate, enabling folate to be absorbed by gastrointestinal tract. GCPII, which is present in a number of tissues at low levels, is overexpressed in neovasculature of most solid tumours and is a target enzyme for diagnosis and treatment of prostate cancer. Normal human prostate express more mRNA coding for a cytosolic GCPII form truncated at the N-terminus (PSM´) than mRNA for membrane-bound GCPII, and this ratio is reversed upon malignant transformation.

Antibody Validation

Boster validates all antibodies on WB, IHC, ICC, Immunofluorescence, and ELISA with known positive control and negative samples to ensure specificity and high affinity, including thorough antibody incubations.

View more details

Applications

M02846-2 is guaranteed for IHC-P, ICC, WB Boster Guarantee

Assay Dilutions Recommendation

The recommendations below provide a starting point for assay optimization. The actual working concentration varies and should be decided by the user.

Western blotting: 1 μg/ml; positive control: LNCaP cell line. Sample preparation: Resuspend approx. 50 mil. cells in 1 ml cold lysis buffer (1% NP-40). Incubate 30 min on ice. Mix lysate with non-reducing/reducing Laemmli SDS-PAGE sample buffer. Both reducing and non-reducing conditions.

Validation Images & Assay Conditions

See full target information FOLH1

Here are featured tools and databases that you might find useful.

• Boster's Pathways Library
• Protein Databases
• Bioscience Research Protocol Resources
• Data Processing & Analysis Software
• Photo Editing Software
• Scientific Literature Resources
• Research Paper Management Tools
• Molecular Biology Software
• Primer Design Tools
• Bioinformatics Tools
• Phylogenetic Tree Analysis